Leroux-Roels G - Search Results

1

Improved CD4⁺ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial.

Leroux-Roels I, Forgus S, De Boever F, Clement F, Demoitié MA, Mettens P, Moris P, Ledent E, Leroux-Roels G, Ofori-Anyinam O; M72 Study Group. Leroux-Roels I, et al. Vaccine. 2013 Apr 19;31(17):2196-206. doi: 10.1016/j.vaccine.2012.05.035. Epub 2012 May 27. Vaccine. 2013. PMID: 22643213 Clinical Trial.

2

Correlation between in vivo humoral and in vitro cellular immune responses following immunization with hepatitis B surface antigen (HBsAg) vaccines.

Leroux-Roels G, Van Hecke E, Michielsen W, Voet P, Hauser P, Pêtre J. Leroux-Roels G, et al. Vaccine. 1994 Jul;12(9):812-8. doi: 10.1016/0264-410x(94)90290-9. Vaccine. 1994. PMID: 7975860 Clinical Trial.

3

Haptoglobin polymorphism and the immune response after hepatitis B vaccination.

Louagie H, Delanghe J, Desombere I, De Buyzere M, Hauser P, Leroux-Roels G. Louagie H, et al. Vaccine. 1993 Sep;11(12):1188-90. doi: 10.1016/0264-410x(93)90041-u. Vaccine. 1993. PMID: 8256500 Clinical Trial.

4

Hepatitis B vaccine containing surface antigen and selected preS1 and preS2 sequences. 1. Safety and immunogenicity in young, healthy adults.

Leroux-Roels G, Desombere I, De Tollenaere G, Petit MA, Desmons P, Hauser P, Delem A, De Grave D, Safary A. Leroux-Roels G, et al. Vaccine. 1997 Nov;15(16):1724-31. doi: 10.1016/s0264-410x(97)00117-5. Vaccine. 1997. PMID: 9364674 Clinical Trial.

5

Hepatitis B vaccine containing surface antigen and selected preS1 and preS2 sequences. 2. Immunogenicity in poor responders to hepatitis B vaccines.

Leroux-Roels G, Desombere I, Cobbaut L, Petit MA, Desmons P, Hauser P, Delem A, De Grave D, Safary A. Leroux-Roels G, et al. Vaccine. 1997 Nov;15(16):1732-6. doi: 10.1016/s0264-410x(97)00118-7. Vaccine. 1997. PMID: 9364675 Clinical Trial.

6

Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system.

Thoelen S, Van Damme P, Mathei C, Leroux-Roels G, Desombere I, Safary A, Vandepapeliere P, Slaoui M, Meheus A. Thoelen S, et al. Vaccine. 1998 Apr;16(7):708-14. doi: 10.1016/s0264-410x(97)00254-5. Vaccine. 1998. PMID: 9562690 Clinical Trial.

7

The first combined vaccine against hepatitis A and B: an overview.

Thoelen S, Van Damme P, Leentvaar-Kuypers A, Leroux-Roels G, Bruguera M, Frei PC, Bakasenas V, Safary A. Thoelen S, et al. Vaccine. 1999 Mar 26;17(13-14):1657-62. doi: 10.1016/s0264-410x(98)00421-6. Vaccine. 1999. PMID: 10194819

8

A hepatitis B vaccine formulated with a novel adjuvant system.

Ambrosch F, Wiedermann G, Kundi M, Leroux-Roels G, Desombere I, Garcon N, Thiriart C, Slaoui M, Thoelen S. Ambrosch F, et al. Vaccine. 2000 Apr 14;18(20):2095-101. doi: 10.1016/s0264-410x(99)00566-6. Vaccine. 2000. PMID: 10715523 Clinical Trial.

9

A comparison of two commercial recombinant vaccines for hepatitis B in adolescents.

Leroux-Roels G, Abraham B, Fourneau M, De Clercq N, Safary A. Leroux-Roels G, et al. Vaccine. 2000 Nov 22;19(7-8):937-42. doi: 10.1016/s0264-410x(00)00217-6. Vaccine. 2000. PMID: 11115719 Clinical Trial.

10

The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population.

Jacques P, Moens G, Desombere I, Dewijngaert J, Leroux-Roels G, Wettendorff M, Thoelen S. Jacques P, et al. Vaccine. 2002 Nov 1;20(31-32):3644-9. doi: 10.1016/s0264-410x(02)00397-3. Vaccine. 2002. PMID: 12399191 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

317 results

Search Page